Literature DB >> 19768405

Designing vaccines for pandemic influenza.

Taisuke Horimoto1, Yoshihiro Kawaoka.   

Abstract

Recent outbreaks of highly pathogenic avian influenza A virus infections (including those of the H5N1 subtype) in poultry and in humans (through contact with infected birds) have raised concerns that a new influenza pandemic will soon occur. Effective vaccines against H5N1 virus are therefore urgently needed. Reverse genetics-based inactivated vaccines have been prepared according to WHO recommendations and licensed in several countries following their assessment in clinical trials. However, the effectiveness of these vaccines in a pandemic is not guaranteed. We must therefore continue to develop alternative pandemic vaccine strategies. Here, we review the current strategies for the development of H5N1 influenza vaccines, as well as some future directions for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19768405      PMCID: PMC6133292          DOI: 10.1007/978-3-540-92165-3_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  47 in total

1.  Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic.

Authors:  Niall P A S Johnson; Juergen Mueller
Journal:  Bull Hist Med       Date:  2002       Impact factor: 1.314

2.  Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.

Authors:  S Li; C Liu; A Klimov; K Subbarao; M L Perdue; D Mo; Y Ji; L Woods; S Hietala; M Bryant
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

3.  Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.

Authors:  Emmie de Wit; Vincent J Munster; Monique I J Spronken; Theo M Bestebroer; Chantal Baas; Walter E P Beyer; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

5.  Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic.

Authors:  A Takada; N Kuboki; K Okazaki; A Ninomiya; H Tanaka; H Ozaki; S Itamura; H Nishimura; M Enami; M Tashiro; K F Shortridge; H Kida
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells.

Authors:  Pascale Massin; Pierre Rodrigues; Monica Marasescu; Sylvie van der Werf; Nadia Naffakh
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Authors:  Iain Stephenson; Karl G Nicholson; Reinhardt Glück; Robert Mischler; Robert W Newman; Abraham M Palache; Neville Q Verlander; Fiona Warburton; John M Wood; Maria C Zambon
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

8.  Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus.

Authors:  T Horimoto; Y Kawaoka
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions.

Authors:  Mark Y Sangster; Janice M Riberdy; Maricela Gonzalez; David J Topham; Nicole Baumgarth; Peter C Doherty
Journal:  J Exp Med       Date:  2003-09-29       Impact factor: 14.307

View more
  14 in total

1.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

Review 2.  Advancements in the development of subunit influenza vaccines.

Authors:  Naru Zhang; Bo-Jian Zheng; Lu Lu; Yusen Zhou; Shibo Jiang; Lanying Du
Journal:  Microbes Infect       Date:  2014-12-18       Impact factor: 2.700

3.  Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.

Authors:  Lindomar Pena; Amy L Vincent; Jianqiang Ye; Janice R Ciacci-Zanella; Matthew Angel; Alessio Lorusso; Philip C Gauger; Bruce H Janke; Crystal L Loving; Daniel R Perez
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  NK cell maturation and function in C57BL/6 mice are altered by caloric restriction.

Authors:  Jonathan F Clinthorne; Eleni Beli; David M Duriancik; Elizabeth M Gardner
Journal:  J Immunol       Date:  2012-12-14       Impact factor: 5.422

5.  New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Authors:  Arnab Basu; Aleksandar Antanasijevic; Minxiu Wang; Bing Li; Debra M Mills; Jessica A Ames; Peter J Nash; John D Williams; Norton P Peet; Donald T Moir; Mark N Prichard; Kathy A Keith; Dale L Barnard; Michael Caffrey; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

Review 6.  Ensuring privacy in the study of pathogen genetics.

Authors:  Sanjay R Mehta; Staal A Vinterbo; Susan J Little
Journal:  Lancet Infect Dis       Date:  2014-04-07       Impact factor: 25.071

7.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

8.  Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir.

Authors:  Irina N Gaisina; Norton P Peet; Han Cheng; Ping Li; Ruikun Du; Qinghua Cui; Kevin Furlong; Balaji Manicassamy; Michael Caffrey; Gregory R J Thatcher; Lijun Rong
Journal:  J Med Chem       Date:  2020-03-02       Impact factor: 7.446

9.  Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Authors:  Rafael Polidoro Alves Barbosa; Bruno Galvão Filho; Luara Isabela Dos Santos; Policarpo Ademar Sales Junior; Pedro Elias Marques; Rafaela Vaz Sousa Pereira; Denise Carmona Cara; Oscar Bruña-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Alexandre Vieira Machado
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

Review 10.  Engineering influenza viral vectors.

Authors:  Junwei Li; Maria T Arévalo; Mingtao Zeng
Journal:  Bioengineered       Date:  2012-08-24       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.